Sen-Jam Pharmaceutical

Sen-Jam Pharmaceutical

Early Stage

Own a stake for health equality; affordable and accessible for all

Own a stake for health equality; affordable and accessible for all

Overview

Raised to Date: Raised: $1,008,951

Total Commitments ($USD)

Platform

Wefunder

Start Date

12/01/2021

Close Date

07/31/2022

Min. Goal
$50,000
Max. Goal
$1,070,000
Min. Investment

$100

Security Type

Convertible Note

Series

Pre-Seed

SEC Filing Type

RegCF    Open SEC Filing

Early Bird Val. Cap

$20,000,000

Valuation Cap

$25,000,000

Discount

20%

Rolling Commitments ($USD)

Status
Funded
Reporting Date

07/30/2022

Days Remaining
Funded
% of Min. Goal
Funded
% of Max. Goal
Funded
Likelihood of Max
Funded
Avg. Daily Raise

$4,187

# of Investors

386

Momentum
Funded
Create a free account today to gain access to KingsCrowd analytics.
Year Founded

2017

Industry

Healthcare & Pharmaceuticals

Tech Sector

Biotech

Distribution Model

B2B

Margin

High

Capital Intensity

High

Location

Huntington, New York

Business Type

Growth

Sen-Jam Pharmaceutical, with a valuation of $25 million, is raising funds on Wefunder. The pharmaceutical company makes highly accessible, safe, and affordable drugs that work. The drugs of Sen-Jam Pharmaceutical combine NSAIDs and antihistamines to prevent inflammation and associated pain. Sen-Jam Pharmaceutical is majorly targeting opioid withdrawal, alcohol hangover prevention, and COVID-19 therapeutic. Jim Iversen and Jackie Iversen founded Sen-Jam Pharmaceutical in August 2017. The current crowdfunding campaign has a minimum target of $50,000 and a maximum target of $1,070,000. The campaign proceeds will be used for product development, regulatory affairs, marketing, communications, and intellectual property advancement.

Summary Profit and Loss Statement

Most Recent Year Prior Year

Revenue

$0

$0

COGS

$0

$0

Tax

$0

$860

 

 

Net Income

$-368,918

$-280,006

Summary Balance Sheet

Most Recent Year Prior Year

Cash

$12,240

$174

Accounts Receivable

$0

$0

Total Assets

$634,559

$670,364

Short-Term Debt

$22,039

$0

Long-Term Debt

$395,075

$0

Total Liabilities

$417,114

$0

Financials as of: 12/01/2021
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
Sen-Jam Pharmaceutical 09/14/2024 Wefunder $80,000,000 $1,241,077 Convertible Note Active RegCF
Sen-Jam Pharmaceutical 01/05/2024 Self Managed - - Convertible Note Funded RegD 506(c)
Sen-Jam Pharmaceutical 01/10/2023 StartEngine $69,979,019 $312,093 Equity - Common Funded RegCF
Sen-Jam Pharmaceutical 07/30/2022 Wefunder $25,000,000 $1,008,951 Convertible Note Funded RegCF
Create a free account today to gain access to KingsCrowd analytics.

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Valuation History

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Employee History

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars

Founder Profile

Sen-Jam Pharmaceutical Founder Jim Iversen on Making Effective and Affordable Drugs

Prescription drug prices in the United States are painfully high. Americans pay more than twice as much as other countries for medication. This can weigh especially heavily on individuals without insurance who are struggling to make ends meet. 


In recognition of this problem, Sen-Jam Pharmaceutical aims to develop and sell affordable and effective oral anti-inflammation medicine. The company is working on eight products to address specific conditions, including COVID-19, opioid withdrawal, and hangovers. We reached out to co-founder and CEO Jim Iversen to learn more about the origins of the business and its plans following the raise.


Note: This interview was conducted over phone and email. It has been lightly edited for clarity and length.


Read Founder Interview

Add to portfolio
Sen-Jam Pharmaceutical on Wefunder 2021
Platform: Wefunder
Security Type: Convertible Note
Valuation: $25,000,000

Follow company

Follow Sen-Jam Pharmaceutical on Wefunder 2021

Buy Sen-Jam Pharmaceutical's Deal Report

Warning: according to the close date for this deal, Sen-Jam Pharmaceutical may no longer be accepting investments.

Sen-Jam Pharmaceutical Deal Report

Get KingsCrowd’s comprehensive report on Sen-Jam Pharmaceutical including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Sen-Jam Pharmaceutical is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Sen-Jam Pharmaceutical deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge